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Iron is a double- edged sword; its deficiency causes anemia 
due to underproduction of hemoglobin, whereas its excess 
can cause organ damage through overproduction of reac-
tive oxygen species [1]. Therefore, the levels of iron in 
the body are maintained within a narrow range by 
sophisticated mechanisms in healthy individuals. The key 
regulator of iron balance in the body is hepcidin, a small 
peptide mainly produced by hepatocytes. Hepcidin was 
originally discovered as an antimicrobial peptide in urine 
[2]; eventually, its presence in human serum was dem-
onstrated using mass spectrometry- based techniques [3]. 
Hepcidin secreted from hepatocytes binds directly to 
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Abstract
Iron overload is considered a risk factor for mortality in patients with hemat-
opoietic malignancies. Hepcidin is a key regulator of systemic iron balance. We 
previously reported dynamic changes of serum hepcidin- 25 levels in patients 
with hematologic malignancies after allogeneic hematopoietic stem cell trans-
plantation (allo- HSCT). In this study, we retrospectively analyzed the association 
of pretransplant hepcidin- 25 levels with overall survival (OS), engraftment, and 
other clinical outcomes of allo- HSCT in patients with hematologic malignancies. 
A total of 166 patients were divided into two groups depending on their pre-
transplant serum hepcidin- 25 levels; their median age was 49.5 years, and the 
median follow- up time was 46.8 months. At 3 years, the patients in the high- 
hepcidin group had a significantly lower OS than those in the low- hepcidin 
group (49.2 vs. 69.0%, respectively; P = 0.006). Multivariate analysis revealed 
that pretransplant serum hepcidin- 25 level, sex, and disease status were inde-
pendently associated with OS. The incidence of platelet engraftment was sig-
nificantly lower in the high- hepcidin group than in the low- hepcidin group, 
whereas no significant differences were observed in neutrophil and reticulocyte 
engraftments between these groups. Hence, pretransplant serum hepcidin levels 
can be a marker for predicting delayed platelet recovery after allo- HSCT.
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ferroportin, the only known iron exporter in the mam-
malian cells, inducing the latter’s internalization and deg-
radation and thereby reducing iron efflux from 
macrophages, hepatocytes and enterocytes [4]. Among 
various forms of mature hepcidin peptides detected in 
serum, hepcidin- 25 is the major form that is responsible 
for the degradation of ferroportin [2, 5].
We previously reported dynamic changes of serum 
hepcidin- 25 levels in patients with hematologic malignan-
cies after allogeneic hematopoietic stem cell transplantation 
(allo- HSCT) [6]. Pretransplant hepcidin- 25 levels of these 
patients were slightly elevated; levels increased further 
during conditioning treatments and reached their peak 
on approximately day 14 before gradually decreasing [6]. 
Our data indicated that serum hepcidin- 25 levels were 
inversely correlated with hematopoietic activity in the set-
ting of allo- HSCT. We also studied the relationship between 
pretransplant serum hepcidin- 25 levels and the outcomes 
of allo- HSCT by analyzing 55 patients with hematologic 
malignancies, and found that elevation of the former was 
associated with an increased risk of early bacterial infec-
tions [7]. However, there was no significant association 
between pretransplant serum hepcidin- 25 elevation and 
the overall survival (OS) of these patients within 100 days 
after allo- HSCT, possibly due to the small number of 
participants and the short follow- up period. In this study, 
we investigated the association of pretransplant serum 
hepcidin- 25 levels with OS, engraftment, and other clinical 
outcomes of allo- HSCT in a greater number of partici-
pants, and with a longer follow- up period.
Patients and Methods
Study population
We retrospectively reviewed the medical records of 177 
adult patients who underwent their first allo- HSCT for 
hematologic malignancies at Kyoto University Hospital 
between July 2006 and August 2013. A total of 166 patients 
whose pretransplant serum hepcidin- 25 level data were 
available, including 55 patients who were enrolled in our 
previous study [7], were included in the analyses. This 
study was performed in accordance with the Helsinki 
Declaration and approved by the Ethics Committee of 
Kyoto University Graduate School and Faculty of Medicine. 
Written informed consent was obtained from all the 
participants.
Serum analysis
Serum samples were obtained in the morning prior to 
the administration of conditioning regimen and stored 
in tubes at −80°C until analysis. Serum hepcidin- 25 levels 
were measured using a liquid chromatography- tandem 
mass spectrometry- based assay system [3]. Other serum 
parameters were measured using standard laboratory 
techniques.
Statistical analysis
The primary endpoint was the impact of pretransplant 
serum hepcidin- 25 levels on overall survival after allo- 
HSCT. The secondary endpoints were the impacts of the 
same on the incidences of relapse, nonrelapse mortality, 
grades G2–4 acute graft- versus- host disease (GVHD), as 
well as recovery of neutrophils (≥500/μL), reticulocytes 
(≥1%), and platelets (≥50,000/μL without transfusion sup-
port) after allo- HSCT; the competing event in the cumu-
lative incidence analyses was defined as death or second 
allo- HSCT without recovery.
The patients were divided into two groups depending 
on their pretransplant levels of serum hepcidin- 25 or fer-
ritin. The cutoff points for the hepcidin- 25 and ferritin 
levels were set at their median values. The patient and 
transplant characteristics between the two groups were 
compared using the Mann–Whitney test or Fisher’s exact 
test, as appropriate. Standard- risk disease was defined as 
complete remission in cases of acute myeloid leukemia, 
acute lymphoblastic leukemia, malignant lymphoma, and 
plasma cell myeloma; untreated or complete remission in 
cases of myelodysplastic syndrome and myeloproliferative 
disorder; and chronic phase in cases of chronic myeloid 
leukemia. High- risk disease was defined as any other dis-
ease state. The conditioning regimen was categorized as 
either myeloablative or reduced intensity according to the 
National Marrow Donor Program and the Center for 
International Blood and Marrow Transplant Research 
operational definitions [8].
Overall survival was estimated using the Kaplan–Meier 
method, and groups were compared using the log- rank 
test. Cumulative incidences of relapse, nonrelapse mortal-
ity, grade 2–4 acute GVHD, and engraftment of neutro-
phils, reticulocytes, and platelets were compared between 
groups using Gray’s test [9].
The Cox proportional- hazard model was applied to 
assess the factors that potentially influenced the study 
endpoints. The following items were considered confound-
ers: serum hepcidin levels (<35 vs. ≥35 ng/mL), the age 
of the recipient (<50 vs. ≥50 years), the sex of the recipi-
ent, diagnosis (myeloid or lymphoid malignancies), risk 
of disease (standard or high risk), source of stem cells 
(HLA- matched- or HLA- mismatched- related donor graft, 
unrelated bone marrow and peripheral blood, or unrelated 
cord blood), ABO matching (matched or mismatched), 
conditioning regimen (myeloablative or reduced intensity), 
and prophylaxis against GVHD (tacrolimus- or 
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cyclosporine- based). For multivariate analysis, stepwise 
backward selection was performed keeping hepcidin- 25 
and variables with P values <0.1. P < 0.05 was considered 
statistically significant.
All the analyses were conducted using EZR (Saitama 
Medical Center, Jichi Medical University, Saitama, Japan), 
which is a graphical user interface for R (The R Foundation 
for Statistical Computing, version 2.13.0) [10].
Results
Characteristics of patients and transplants
The characteristics of the patients and transplants are 
shown in Table 1. The median pretransplant serum hep-
cidin- 25 level was 35 ng/mL, which was higher than that 
of healthy volunteers (7.8 ± 7.0 ng/mL, n = 63). Patients 
were divided into two groups (n = 83 each) according 
to the pretransplant serum hepcidin- 25 levels: the low- 
hepcidin group (<35 ng/mL) and the high- hepcidin group 
(≥35 ng/mL). There were no significant differences in 
patient and transplant characteristics between the low- and 
high- hepcidin groups (Table 1).
OS, relapse, and nonrelapse mortality
Median follow- up time after allo- HSCT among survivors 
was 46.8 months. During the follow- up period, 16 patients 
relapsed and 11 died without relapse in the low- hepcidin 
group, whereas 30 relapsed and 14 died without relapse 
in the high- hepcidin group. The actual causes of non-
relapse mortality (NRM) are listed in Table S1. Eight 
and nine patients in the low- hepcidin and high- hepcidin 
groups, respectively, received second allo- HSCT without 
recovery (Table S2). At 3 years, the patients in the high- 
hepcidin group had a significantly lower OS than those 
in the low- hepcidin group (49.2 vs. 69.0%, respectively; 
P = 0.006) (Fig. 1, panel a). No significant difference 
was observed between these groups in the cumulative 
incidences of NRM, disease relapse, or grade 2−4 acute 
GVHD (Fig. 1, panels b−d). On univariate analysis, pre-
transplant serum hepcidin- 25 ≥ 35 ng/mL, male sex, 
and high- risk disease status were significant risk factors 
for inferior OS, whereas patient age, disease category 
(myeloid or lymphoid), source of stem cells, ABO match-
ing, conditioning regimens, and GVHD prophylaxis 
methods did not affect OS (Table 2). Multivariate analysis 
Table 1. Characteristics of patients and transplants.
Variables Total
n = 166
Hepcidin- 25, <35 ng/mL
n = 83
Hepcidin- 25, ≥35 ng/mL
n = 83
P value
Age at transplant (years)
Median (range) 49.5 (17–66) 47 (17–65) 51 (19–66) 0.22
Sex
Male 92 48 44 0.64
Female 74 35 39
Disease
Myeloid malignancies 103 49 54 0.52
Lymphoid malignancies 63 34 29
Risk of disease
Standard 100 53 47 0.43
High 66 30 36
Source of stem cells
HLA- matched related 31 18 13 0.66
HLA- mismatched related 13 5 8
Unrelated BM or PB1 75 38 37
Unrelated CB 47 22 25
ABO blood- type matching
Matched 67 32 35 0.75
Mismatched 99 51 48
Conditioning regimen
Myeloablative intensity 79 45 34 0.12
Reduced intensity 87 38 49
GVHD prophylaxis
Tacrolimus- based 143 68 75 0.18
Cyclosporine- based 23 15 8
1Among the stem cell sources from unrelated donors, all but 1 were BM.
Patient and transplant characteristics between two groups were compared using the Mann–Whitney U- test or Fisher’s exact test, as appropriate. HLA, 
human leukocyte antigen; BM, bone marrow; PB, peripheral blood; CB, cord blood; GVHD, graft- versus- host disease; tacrolimus- based, tacrolimus 
with or without other agents; cyclosporine- based, cyclosporine with or without other agents.
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revealed that pretransplant serum hepcidin- 25 level, sex 
and disease status were independently associated with 
OS (Table 2).
Engraftment
Next, we analyzed the incidences of engraftment according 
to pretransplant hepcidin- 25 levels. No significant differ-
ences were observed in neutrophil and reticulocyte engraft-
ments between the high- and low- hepcidin groups (Fig. 2, 
panels a and b). In contrast, platelet engraftment was 
significantly lower in the high- hepcidin group than in 
the low- hepcidin group (Figure 2, panel c); the probability 
of platelet engraftment at day 50 in the high- hepcidin 
group was 56.6% compared to 78.2% in the low- hepcidin 
group (P = 0.002). On univariate analyses, only unrelated 
cord blood transplantation was a significant risk factor 
for inferior neutrophil and reticulocyte engraftments 
(Table 3). As for platelet engraftment, pretransplant serum 
hepcidin- 25 levels ≥35 ng/mL, high- risk disease status, 
and unrelated cord blood transplantation were significant 
risk factors for inferior engraftment on univariate analysis; 
all these factors in addition to male sex of the recipient 
were significant risk factors for inferior engraftment on 
multivariate analysis (Table 3).
Comparison of pretransplant serum ferritin 
and hepcidin- 25 levels as predictive markers 
of transplant outcome
Serum hepcidin- 25 levels have been shown to positively 
correlate with serum ferritin level [3]. Because pretrans-
plant serum ferritin levels have been demonstrated to 
be an independent risk factor for the survival after allo- 
HSCT [11], we compared the significance of pretransplant 
serum ferritin and hepcidin- 25 levels on the outcome 
of allo- HSCT in our cohort. Consistent with previous 
reports [3, 12], pretransplant serum hepcidin- 25 levels 
were positively correlated with levels of serum ferritin 
(R = 0.57, P < 0.001, Fig. S1). We divided the patients 
into two groups according to the pretransplant ferritin 
levels; the cut- off was set at 694 ng/mL, the median 
value. Consistent with previous reports [13, 14], patients 
in the high- ferritin group had a significantly lower OS 
than those in the low- ferritin group at 3 years post 
allo- HSCT (46 vs. 72%, P = 0.001; Fig. S2, panel a). 
No significant difference was observed in the cumulative 
incidences of NRM, disease relapse, grade 2−4 acute 
GVHD (Fig. S2, panels b−d), and neutrophil and reticu-
locyte engraftments (Fig. S3, panels a and b) between 
the high- and low- ferritin groups. The incidence of platelet 
Figure 1. Outcome of allogeneic hematopoietic stem cell transplantation in patients with hematological malignancies stratified by pretransplant 
hepcidin- 25 levels. Patients were divided into two groups; solid lines indicate the low- hepcidin group (<35 ng/mL), and broken lines indicate the high- 
hepcidin group (≥35 ng/mL). (a) Overall survival (OS). (b) Cumulative incidence of nonrelapse mortality. (c) Cumulative incidence of relapse. (d) 
Cumulative incidence of grade 2–4 acute graft- versus- host disease (GVHD).
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engraftment tended to be lower in the high- ferritin group 
than in the low- ferritin group, with borderline signifi-
cance (Fig. S3, panel c, P = 0.05 using Gray’s test). 
When we subjected the pretransplant serum ferritin level 
to the multivariate analysis, serum ferritin level ≥694 ng/mL 
was not a significant risk factor for inferior platelet 
engraftment (P = 0.073). Furthermore, we divided the 
high- and low- ferritin groups into high- and low- hepcidin 
subgroups using their median values (57 ng/mL and 
19 ng/mL for the high- and low- ferritin groups, respec-
tively) as cut- offs. In the low- ferritin group, pretransplant 
hepcidin- 25 levels had little effect on the incidence of 
platelet recovery (Fig. 3, panel a). In contrast, the inci-
dence of platelet recovery in the high- ferritin group was 
significantly lower in the high- hepcidin subgroup than 
in the low- hepcidin subgroup (Fig. 3, panel b, P = 0.022 
using Gray’s test).
Discussion
Previous studies showed an unfavorable impact of elevated 
serum hepcidin- 25 levels on the survival of patients with 
primary myelofibrosis and non- Hodgkin lymphoma [15, 16]. 
In hemodialysis patients, elevated serum hepcidin- 25 levels 
were associated with increased risks of cardiovascular events 
[17]. In this study, we investigated the association of 
pretransplant serum hepcidin levels and the outcome of 
allo- HSCT. Consistent with our previous report, the median 
pretransplant serum hepcidin- 25 level (35 ng/mL) was 
higher than that of healthy volunteers [6]. In this study, 
we found that elevated pretransplant serum hepcidin- 25 
levels (≥35 ng/mL) predicted inferior OS after allo- HSCT. 
We also found that elevated pretransplant serum hepcidin-
 25 levels were associated with a lower incidence of platelet 
engraftment.
Table 2. Univariate and multivariate analyses of overall survival.
Category Univariate Multivariate
HR P value HR P value
Hepcidin- 25
<35 ng/mL 1 1












High 2.31 <0.001 2.37 <0.001
Source of stem cells
HLA- matched related 1
HLA- mismatched related 1.66 0.3
Unrelated BM/PB 1.54 0.23
Unrelated CB 1.47 0.32









The Cox proportional- hazard model was applied to calculate hazard 
 ratios (HRs) and P values. P values <0.05 are shown in bold- type. HLA, 
human leukocyte antigen; BM, bone marrow; PB, peripheral blood; CB, 
cord blood; GVHD, graft- versus- host disease; tacrolimus- based, tacroli-
mus with or without other agents; cyclosporine- based, cyclosporine 
with or without other agents.
Figure 2. Outcome of allogeneic hematopoietic stem cell transplantation in patients with hematological malignancies stratified by pretransplant 
hepcidin- 25 levels. Solid lines indicate the low- hepcidin group (<35 ng/mL), and broken lines indicate the high- hepcidin group (≥35 ng/mL). (a) 
Neutrophil engraftment. (b) Reticulocyte engraftment. (c) Platelet engraftment.
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Table 3. Univariate and multivariate analysis of engraftment.
Categories Neutrophils ≥500 Reticulocytes ≥1% Platelets ≥50,000
Univariate Multivariate Univariate Multivariate Univariate Multivariate
HR P value HR P value HR P value HR P value HR P value HR P value
Hepcidin
<35 ng/mL 1 1 1 1 1 1
≥35 ng/mL 1.04 0.79 1.02 0.9 0.91 0.55 0.89 0.49 0.59 0.003 0.62 0.008
Age (years)
<50 1 1 1
≥50 1.02 0.92 1.04 0.83 1.03 0.85
Sex
Male 1 1 1 1
Female 1.01 0.95 1.06 0.71 1.36 0.077 1.44 0.037
Disease
Myeloid 1 1 1
Lymphoid 1.1 0.57 1.22 0.25 0.91 0.59
Risk
Standard 1 1 1 1
High 0.8 0.17 0.94 0.7 0.65 0.021 0.67 0.031
Sources of stem cells
HLA- matched related 1 1 1 1 1 1
HLA- mismatched 
related
1.09 0.79 1.08 0.82 1.22 0.56 1.26 0.58 0.13 0.7 0.33
Unrelated BM/PB 0.99 0.98 0.99 0.96 1.2 0.42 1.21 0.4 0.77 0.25 0.85 0.49
Unrelated CB 0.55 0.014 0.55 0.013 0.47 0.003 0.48 0.003 0.36 <0.001 0.37 <0.001
ABO matching
Matched 1 1 1
Mismatched 1.14 0.43 0.85 0.35 0.99 0.96
Conditioning
Myeloablative 1 1 1
Reduced 1.16 0.34 1.12 0.5 1.09 0.63
GVHD prophylaxis
Tacrolimus 1 1 1
Cyclosporine 1.02 0.93 0.71 0.17 1.05 0.84
The Cox proportional- hazard model was applied to calculate hazard ratios (HRs) and P values. P values <0.05 are shown in bold- type. HLA, human 
leukocyte antigen; BM, bone marrow; PB, peripheral blood; CB, cord blood; GVHD, graft- versus- host disease; tacrolimus- based, tacrolimus with or 
without other agents; cyclosporine- based, cyclosporine with or without other agents.
Figure 3. Platelet engraftment after allogeneic hematopoietic stem cell transplantation in patients with hematological malignancies stratified by 
pretransplant hepcidin- 25 levels. When dividing into subgroups, the cutoff values of pretransplant serum hepcidin- 25 levels were set to the median 
values in each group (19 ng/mL for the low- ferritin group and 57 ng/mL for the high- ferritin group). Solid lines indicate the low- hepcidin subgroups, 
and broken lines indicate the high- hepcidin subgroups. (a) Low- ferritin group. (b) High- ferritin group.
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Hepcidin production by hepatocytes is controlled by 
various factors; for example, iron, interleukin- 6, bone 
morphogenetic protein 6, and oncostatin M strongly induce 
hepcidin production [18–21], whereas hypoxia, growth 
differentiation factor 15, and erythroferrone suppress it 
[22–24]. Among these factors, iron strongly induces hep-
cidin production. Since expression of both hepcidin and 
ferritin are upregulated by systemic iron overload [25, 26], 
it follows that serum hepcidin- 25 levels are positively cor-
related with those of serum ferritin [3, 12]. Consistently, 
we observed a positive correlation between pretransplant 
serum levels of ferritin and hepcidin- 25 (Figure S1). In 
patients with hematopoietic malignancies, iron overload 
frequently occurs due to repeated red blood cell transfu-
sions and/or ineffective erythropoiesis [27]. In hematologic 
malignancies such as myelodysplastic syndromes, elevation 
of serum ferritin is regarded as a risk factor for mortality 
[28, 29]. Elevation of pretransplant serum ferritin has 
been shown to be a prognostic factor predicting an increase 
in NRM and inferior OS in a number of studies includ-
ing our own [13, 14]. Therefore, elevated pretransplant 
serum hepcidin- 25 levels probably reflected iron overload 
and predicted inferior OS after allo- HSCT, similar to the 
level of serum ferritin (Fig. 1, panel a).
In this study, we unexpectedly found that elevation of 
pretransplant hepcidin- 25 levels was significantly associated 
with lower incidence of platelet engraftment on both 
univariate and multivariate analyses. Since hepatic hepcidin 
production is suppressed by active erythropoiesis, increased 
pretransplant serum hepcidin- 25 levels might have reflected 
impaired hematopoietic environments not suitable for 
platelet engraftment. Additionally, the incidence of early 
bacterial infection was higher in the high- hepcidin group 
than in the low- hepcidin group as we previously reported 
[7]; therefore, such infections might have negatively affected 
platelet engraftment in the high- hepcidin group. In the 
current cohort, the cumulative incidence of early bacterial 
infections in the low- and high- hepcidin groups were 
24.5% and 44.6%, respectively; P = 0.027 using Gray’s 
test. Still, the reason why only platelet engraftment, not 
neutrophil or erythroid engraftment, was delayed is unclear. 
Among the three cell lineages, the megakaryocytic may 
be most sensitive to an impaired hematopoietic environ-
ment or infection. Alternatively, iron overloaded status 
may preferentially suppress megakaryopoiesis. This hypoth-
esis is supported by observations that iron deficiency 
stimulates megakaryocytic differentiation and causes 
thrombocytosis [30], and that reduction in iron mass by 
phlebotomy can increase platelet counts in patients with 
liver cirrhosis [31]. Consistently, the incidence of platelet 
engraftment tended to be lower in the high- ferritin group 
than in the low- ferritin group (Fig. S3). However, eleva-
tion of pretransplant serum ferritin levels was not 
significantly associated with delayed platelet engraftment 
on multivariate analyses in our cohort. Additionally, the 
elevation of pretransplant serum hepcidin- 25 levels 
(>57 ng/mL) still had a significant adverse effect on platelet 
engraftment in those patients with high pretransplant fer-
ritin levels (>694 ng/mL). Thus, the adverse impact of 
the elevation of pretransplant hepcidin levels on platelet 
recovery appeared to be stronger than that of pretransplant 
serum ferritin levels. It is noteworthy that the incidence 
of platelet recovery at day 50 was only 49% in our cohort 
if both pretransplant serum ferritin and hepcidin- 25 levels 
were high.
In summary, pretransplant serum hepcidin- 25 levels 
negatively impacted OS and platelet recovery after allo- 
HSCT. The pretransplant serum hepcidin level can poten-
tially be a marker for predicting delayed platelet recovery 
after allo- HSCT. Since this is a relatively small, retrospec-
tive, and single institutional study, our observations require 
verification in future studies. The mechanism of how 
pretransplant serum hepcidin levels lead to a lower inci-
dence of platelet recovery also remains to be 
determined.
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